Document is current

Article History

Received: 23 March 2022

Accepted: 6 November 2022

First Online: 16 November 2022

Change Date: 16 December 2022

Change Type: Update

Change Details: The hyperlinking of the additional file 1 has been corrected.

Declarations

:

: This is a secondary analysis of population-level data from the National Program of Cancer Registries-Surveillance, Epidemiology, and End Results (NPCR-SEER) databases; thus, all data were anonymized before use, and ethics approval and patient consent to participate in accordance with the Declaration of Helsinki were not required.

: Not applicable as this is a secondary analysis of population-level data from the NPCR-SEER databases.

: J.K. declares that they have no competing interests. B.Y. and K.B. are employees and stockholders of AstraZeneca. S.M.K was an employee of AstraZeneca during the initial conceptual development of the study through the second draft of the manuscript, is currently an employee of Sanofi, and is currently a stockholder of AstraZeneca and Sanofi. R.T.S. serves as an advisory board member for Agios, Clovis, Debiopharm, Exelixis Pharmaceuticals, Incyte, Merck, QED, and Seattle Genetics, and has received research funding from Exelixis Pharmaceuticals, Merck, Pieris, Rafael Pharmaceuticals, and Taiho.